- Home
- BIAF vs VYNE Comparison
BIAF vs VYNE Comparison
Compare BIAF & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- VYNE
- Stock Information
- Founded
- BIAF 2014
- VYNE 2003
- Country
- BIAF United States
- VYNE United States
- Employees
- BIAF N/A
- VYNE N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- VYNE Health Care
- Exchange
- BIAF Nasdaq
- VYNE Nasdaq
- Market Cap
- BIAF 7.6M
- VYNE 7.9M
- IPO Year
- BIAF 2022
- VYNE 2018
- Fundamental
- Price
- BIAF $0.15
- VYNE $0.30
- Analyst Decision
- BIAF Hold
- VYNE Buy
- Analyst Count
- BIAF 1
- VYNE 2
- Target Price
- BIAF N/A
- VYNE $8.00
- AVG Volume (30 Days)
- BIAF 12.0M
- VYNE 1.7M
- Earning Date
- BIAF 11-13-2025
- VYNE 11-06-2025
- Dividend Yield
- BIAF N/A
- VYNE N/A
- EPS Growth
- BIAF N/A
- VYNE N/A
- EPS
- BIAF N/A
- VYNE N/A
- Revenue
- BIAF $7,681,059.00
- VYNE $476,000.00
- Revenue This Year
- BIAF N/A
- VYNE N/A
- Revenue Next Year
- BIAF $20.04
- VYNE N/A
- P/E Ratio
- BIAF N/A
- VYNE N/A
- Revenue Growth
- BIAF 4.99
- VYNE N/A
- 52 Week Low
- BIAF $0.16
- VYNE $0.28
- 52 Week High
- BIAF $2.26
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- BIAF 33.56
- VYNE 31.15
- Support Level
- BIAF $0.24
- VYNE $0.29
- Resistance Level
- BIAF $0.45
- VYNE $0.33
- Average True Range (ATR)
- BIAF 0.03
- VYNE 0.02
- MACD
- BIAF -0.01
- VYNE 0.02
- Stochastic Oscillator
- BIAF 5.79
- VYNE 31.63
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.